Contact
Subscribe
Contact
Subscribe

,

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

Date : December 18, 2024

Replay of the virtual KOL event featuring Prof. Mohamad Mohty, MD, PhD (Saint-Antoine Hospital – AP-HP) and Dr. Monzr M. Al Malki, MD (City of Hope) where they discussed: 

  • Unmet medical needs in acute Graft-versus-Host Disease, 
  • The latest data on MaaT013 from the Early Access Program, as presented at the 2024 ASH Annual Meeting,
  • The potential of microbiome immunomodulation in their clinical practice.

Dowload the presentation here.

Find below the video summary:

00:00 to 8:40 : Introduction by Hervé Affagard, CEO and co-founder of MaaT Pharma

8:41 to 14:55 : Unmet need for MaaT013 in GvHD in Europe and in the US with Dr. Monzr M. Al Malki M.D

14:56 to 26:00 : Results from the Early Access Program in Europe with Pr Mohamad Mohty, M.D

26:01 to 29:45 : Upcomming milestones for MaaT Pharma with Hervé Affagard

29:46 to 56:46 : Q&A session, with Pr Mohamad Mohty, M.D, Dr. Monzr M. Al Malki M.D, Hervé Affagard, and Gianfranco Pittari M.D. PhD, Chief Medical Officer of MaaT Pharma

[maat_prev_next_nav]

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at MaaT Pharma. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson’s Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company’s scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of Xervyteg® in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

Linkedin-in

CEO and co-founder

Hervé Affagard

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

Linkedin-in Twitter
MaaT Pharma in the News